Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity
Authors
Shannon, V. R.Anderson, R.
Blidner, A.
Choi, J.
Cooksley, Timothy J
Dougan, M.
Glezerman, I.
Ginex, P.
Girotra, M.
Gupta, D.
Johnson, D. B.
Suarez-Almazor, M. E.
Rapoport, B. L.
Affiliation
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.Issue Date
2020
Metadata
Show full item recordAbstract
The immune checkpoints associated with the CTLA-4 and PD-1 pathways are critical modulators of immune activation. These pathways dampen the immune response by providing brakes on activated T cells, thereby ensuring more uniform and controlled immune reactions and avoiding immune hyper-responsiveness and autoimmunity. Cancer cells often exploit these regulatory controls through a variety of immune subversion mechanisms, which facilitate immune escape and tumor survival. Immune checkpoint inhibitors (ICI) effectively block negative regulatory signals, thereby augmenting immune attack and tumor killing. This process is a double-edged sword in which release of regulatory controls is felt to be responsible for both the therapeutic efficacy of ICI therapy and the driver of immune-related adverse events (IrAEs). These adverse immune reactions are common, typically low-grade and may affect virtually every organ system. In the early clinical trials, lung IrAEs were rarely described. However, with ever-expanding clinical applications and more complex ICI-containing regimens, lung events, in particular, pneumonitis, have become increasingly recognized. ICI-related lung injury is clinically distinct from other types of lung toxicity and may lead to death in advanced stage disease. Thus, knowledge regarding the key characteristics and optimal treatment of lung-IrAEs is critical to good outcomes. This review provides an overview of lung-IrAEs, including risk factors and epidemiology, as well as clinical, radiologic, and histopathologic features of ICI-related lung injury. Management principles for ICI-related lung injury, including current consensus on steroid refractory pneumonitis and the use of other immune modulating agents in this setting are also highlighted.Citation
Shannon VR, Anderson R, Blidner A, Choi J, Cooksley T, Dougan M, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020:1-13.Journal
Supportive Care in CancerDOI
10.1007/s00520-020-05708-2PubMed ID
32880733Additional Links
https://dx.doi.org/10.1007/s00520-020-05708-2Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s00520-020-05708-2
Scopus Count
Collections
Related articles
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
- Authors: Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL
- Issue date: 2020 Dec
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
- Authors: Cooksley T, Girotra M, Ginex P, Gordon RA, Anderson R, Blidner A, Choi J, Dougan M, Glezerman I, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL
- Issue date: 2020 Dec
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
- Authors: Suarez-Almazor ME, Pundole X, Abdel-Wahab N, Johnson DB, Gupta D, Glezerman I, Cooksley T, Anderson R, Blidner A, Choi J, Dougan M, Ginex P, Girotra M, Shannon VR, Rapoport BL
- Issue date: 2020 Dec
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
- Authors: Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Lacouture ME
- Issue date: 2020 Dec
- Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
- Authors: Shao J, Wang C, Ren P, Jiang Y, Tian P, Li W
- Issue date: 2020 May 29